KPTI
NASDAQKaryopharm Therapeutics Inc.
News · 26 weeks630%
2026-03-012026-08-23
Mix2290d
- Other11(50%)
- SEC Filings5(23%)
- Earnings3(14%)
- Analyst2(9%)
- Insider1(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Karyopharm Therapeutics Inc.SCHEDULE 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
- SECSEC Form 10-Q filed by Karyopharm Therapeutics Inc.10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- SECKaryopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- PRKaryopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the Journal of Clinical Oncology; Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis –– Total Revenue was $33.4 Million, and U.S. XPOVIO® (selinexor) Net Product Revenue was $30.8 Million for the Second Quarter of 2026 –– Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Karyopharm Therapeutics Inc.SCHEDULE 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
- PRKaryopharm to Report Second Quarter 2026 Financial Results on August 13, 2026-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --NEWTON, Mass., Aug. 10, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates.To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Kar
- PRKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of
- ANALYSTKaryopharm Therapeutics downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Karyopharm Therapeutics from Outperform to Neutral and set a new price target of $3.00
- ANALYSTKaryopharm Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral and set a new price target of $3.00
- SECSEC Form 8-K filed by Karyopharm Therapeutics Inc.8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- INSIDEREVP, Chief Development Officer Poulton Stuart sold $1,342 worth of shares (189 units at $7.10), decreasing direct ownership by 0.20% to 94,632 units (SEC Form 4) (withholding tax)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- PRKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of Therapy –NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage
- PRKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) –– A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo Arm in the mITT Population; Company Plans to Continue to Follow Patients for Longer-Term Outcomes –– The Safety and Tolerability Profile was Consistent with the Known Profile of Selinexor; No New Safety Signals Were Observed –– Company Prioritizing its Resources on its Myelofibrosis and Multiple Myeloma Programs; Company to Reduce Planned Investment in Endometrial Cancer –NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical com
- SECSEC Form 8-K filed by Karyopharm Therapeutics Inc.8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- PRKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of June 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consec
- PRKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m. ET. The event will feature the Company's senior management team and Robert Coleman, MD, FACOG, FACS, a globally recognized gynecologist oncologist and Principal Investigator of the Phase 3 XPORT-EC-042 trial.Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available on June 8, 2026 at approximately 2:00pm ET under "Events and Pre
- PRKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival –– Selected by EHA's Scientific Program Committee as One of the Top Abstracts to be Presented – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-breaking abstract was accepted for an oral presentation at the 2026 European Hematology Association (EHA) Congress, taking place June 11 to 14 in Stockholm, Sweden. The SENTRY presentation was selected by EHA's Scientific Program
- PRKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecified Subgroups –– Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline; Reductions in Symptoms Were Consistent Across Each Domain –– Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib, with Early Separation of the Kaplan-Meier Curves –– Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – NEWTON, Mass., June 2, 2026 /PRNewswire/ -- Karyopharm The
- PRKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of May 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of
- PRKaryopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial –– Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET –NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a conference call on June 2, 2026 at 2:00 p.m. ET featuring the Company's senior management team and Dr. John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and principal investigator of the Phase 3 SENTRY trial. The cal
- SECKaryopharm Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- PRKaryopharm to Participate at the 2026 Jefferies Global Healthcare ConferenceNEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2026 Jefferies Global Healthcare Conference in a fireside chat on Thursday, June 4, 2026 at 8:10 a.m. ET in New York, NY.A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.About Karyopharm TherapeuticsKaryopharm Therapeutics is a commercial-stage pharmace
- SECSEC Form S-8 filed by Karyopharm Therapeutics Inc.S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- SECSEC Form S-8 filed by Karyopharm Therapeutics Inc.S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- INSIDERDirector Oliger Christy J. was granted 15,508 shares (SEC Form 4)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
KPTI FAQ
7 questionsWhat does Karyopharm Therapeutics Inc. do?
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with...Where does KPTI stock trade?
Karyopharm Therapeutics Inc. (KPTI) is listed on NASDAQ.What sector and industry is KPTI in?
Karyopharm Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Karyopharm Therapeutics Inc. go public?
Karyopharm Therapeutics Inc. (KPTI) completed its IPO in 2013.What are analysts saying about KPTI?
Karyopharm Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $300.00 price target on 2026-07-31.What companies are similar to KPTI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KPTI side-by-side with any of them on Quantisnow.How can I track KPTI on Quantisnow?
Quantisnow aggregates Karyopharm Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KPTI to receive live email and push alerts on every new disclosure.